biotech partnership

Merck partners with Infinimmune for next-gen antibody drugs, gaining exclusive rights to candidates from AI-powered platform with up to $838M in potential milestone payments.

Genenta rebrands to Saentra Forge, shifting focus toward defense and aerospace acquisitions while maintaining biotech research programs with glioblastoma trial results accepted for publication.